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Background and purpose — While development in hip fracture 
incidence and mortality is well examined, none has yet looked 
at the temporal trends regarding prevalence of co-morbidities. 
Therefore we investigated changes in incidence of fi rst hip frac-
ture, co-morbidity prevalence, 30 day- and 1-year mortality in hip 
fracture patients in the Danish population during the period 1999 
to 2012.
Patients and methods — Patients > 18 years admitted with a 
fractured hip in Denmark between 1996 and 2012 were identi-
fi ed with data for the period 1999–2012 being analyzed regarding 
prevalence of co-morbidities, incidence, and mortality.
Results — 122,923 patients were identifi ed. Incidence in the 
whole population declined but sex-specifi c analysis showed no 
changes for men. For the whole study population, 30-day and 
1-year mortality remained unchanged. Age at time of fi rst hip 
fracture also remained unchanged. Of the included co-morbid-
ities a decrease in prevalence of malignancy and dementia in 
women was found while there was an increase in the prevalence 
of all remaining co-morbidities, except hemi- or paraplegia for 
both sexes, rheumatic diseases for women, and for men diabetes 
with complications, myocardial infarction, AIDS/HIV, and malig-
nancy.
Interpretation — While hip fracture incidence declined for 
women it was unchanged for men; likewise, 30-day and 1-year 
mortality rates together with age at fi rst fracture remained 
unchanged. When these results are compared with the relatively 
large increase in the prevalence of co-morbidities, it does not seem 
likely that the increased disease burden is affecting either the inci-
dence or the mortality.
■
Patients sustaining a hip fracture are known to have increased 
mortality and morbidity compared with the general popula-
tion and as the population gets older an increased incidence 
of hip fractures could be expected (Kanis 1993). Studies on 
the development in hip fracture incidence have found diverg-
ing results with some reporting decreasing incidence (Kannus 
et al. 2006, Abrahamsen and Vestergaard 2010, Lippuner et 
al. 2011, Nilson et al. 2013, Jean et al. 2013, Korhonen et al. 
2013) and others increasing incidence (Mann et al. 2008). 
Also, hip fracture patients have an excess mortality (Haentjens 
et al. 2010) with risk factors including co-morbidity (Barone 
et al. 2009). While the development in hip fracture incidence 
and mortality has already been examined, few studies have 
looked at the development in co-morbidity and it is unclear 
whether hip fracture incidence and mortality change with the 
prevalence of co-morbidities. The purpose of this descriptive 
study was to investigate the changes in incidence of fi rst hip 
fracture, co-morbidity, 30-day and 1-year mortality in hip 
fracture patients in the Danish population during the period 
1999 to 2012.
Patients and methods 
Study population
Data were collected from the Danish National Patient
Registry (DNPR) on all patients above 18 years, sustaining a 
hip fracture (ICD-10 codes: DS720, DS721 or DS722) during 
the period January 1, 1996 to December 31, 2012. For patients 
sustaining more than 1 hip fracture during the period, only 
the fi rst was included and used as index fracture for survival 
analysis. 154,062 patients sustained a hip fractures during 
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this period. To make sure that only the fi rst hip fracture was 
included and thus reducing the risk of fi nding a false decrease 
in hip fracture incidence and co-morbidities, data for the fi rst 
3 years were excluded as a washout period. As such, only data 
from the period 1999 to 2012 were analyzed resulting in the 
inclusion in the study of 122,923 patients with a hip fracture. 
Data collected on the individual patient included age, sex, frac-
ture type, co-morbidity, and time of death. The co-morbidities 
found in the Charlson Co-morbidity Index (CCI) were included 
in the study with data on co-morbidities registered prior to the 
fracture being retrieved from the DNPR and coded as described 
by Quan et al. (2005). The following co-morbidities were 
thus included: myocardial infarction, congestive heart failure, 
peripheral vascular disease, cerebrovascular disease, dementia, 
chronic pulmonary disease, rheumatic disease, peptic ulcer 
disease, moderate or severe liver disease, mild liver disease, 
diabetes without chronic complication, diabetes with chronic 
complication, hemiplegia or paraplegia, metastatic solid tumor, 
any malignancy, AIDS/HIV, and renal disease.
National patient registry data
In Denmark, all citizens have a unique, non-reusable, 10-digit 
civil registration number (CRN) assigned by the Civil Regis-
tration System (CRS). The CRS contains demographic infor-
mation on all citizens residing legally in Denmark including 
vital status and emigration. The CRN is used in all public 
records making it possible to link different information from 
national registries for the unique individual. This provides 
excellent traceability and allows almost complete follow-up 
(Schmidt et al. 2014). 
Through the use of the CRN, all contacts and admissions to 
Danish hospitals are registered in the DNPR which contains 
information on all non-psychiatric hospital admissions 
dating back to 1977 and has since 1995 also included data 
on outpatient visits and psychiatric admissions (Lynge 
et al. 2011). For this study, data on discharge diagnosis 
or secondary diagnostic codes were used in the form of 
International Disease Classifi cation 10 (ICD-10) codes. When 
using data from registries 2 important measures of quality 
are validity and completeness, which vary with the different 
diagnosis codes (Schmidt et al. 2015). To our knowledge 
no completeness study has been performed on hip fractures 
reported to the DNPR, but since data completeness depends 
on hospitalization patterns and diagnostic accuracy, one would 
expect that conditions such as hip fracture, which should 
always lead to a hospital encounter, are registered consistently 
in the DNPR with a high level of completeness.
Data on the Danish population size for the different years 
during the period 1999–2012 were obtained from http://www.
dst.dk/da/Statistik/statistikbanken.
Statistics
All included continuous variables were non-normally distrib-
uted and were thus analyzed using Mann–Whitney U-tests. 
The Cochran–Armitage trend test was used to test for trends 
in development in prevalence of co-morbidities. The develop-
ment in incidence and mortality over time was assessed using 
negative binomial regression analysis since overdispersion 
was found when performing Poisson regression analysis, with 
patients sustaining a fracture being removed from the popu-
lation at risk for the purpose of calculating incidence rates. 
Person-time was calculated based on the number of individuals 
at risk on January 1 each year in Denmark assuming all were 
followed for the subsequent year. P-values < 0.05 were consid-
ered signifi cant. Statistical analyses were conducted using SAS 
version 9.4 (SAS Institute, Cary, NC, USA).
Ethics, funding, and potential confl icts of interest
According to Danish law, ethical committee approval is not 
required for this type of observational database study. The 
data were obtained through secure remote access to Statis-
tics Denmark (ref. 704670). The study was approved by the 
Danish Data Protection Agency. No funding was received for 
this study. No competing interest was declared for any of the 
authors.
Results
122,923 patients sustained their fi rst hip fracture during the 
study period (Table 1). From 1999 to 2012, the hip fracture 
incidence in the whole population declined from 182 to 137 
per 100,000 (p < 0.001) but gender-specifi c analysis showed 
that a decrease was evident only for women (256 to 181 per 
100,000, p < 0.001) since the changes for men were not sta-
tistically signifi cant (107 to 93 per 100,000, p = 0.09) (Figure 
1). At the same time, the median age at time of fi rst hip frac-
ture remained largely unchanged (Figure 2). For the whole 
population, 30-day together with 1-year mortality remained 
unchanged (9.7% to 10.3%, p = 0.9 and 28.2% to 27.4%, p = 
0.4, respectively) with sex-specifi c analysis showing the same 
trends for men (13.7% to 12.5%, p = 0.5 and 33.5% to 31.3%, 
p = 0.5) and women (8.1% to 9.1%, p = 0.9 and 26.0% to 
25.5% p = 0.2) (Figures 3 and 4). 
Of the included co-morbidities a trend with a decrease in 
prevalence of malignancy and dementia in women was found 
while an increase in the prevalence of all remaining co-mor-
bidities, except hemi- or paraplegia for both genders, rheu-
matic diseases for women, and for men diabetes with com-
plications, myocardial infarction, AIDS/HIV, and malignancy 
was found, with the largest increase in prevalence seen for 
congestive heart failure, moderate to severe liver disease, and 
renal disease, with the largest increments found for congestive 
heart failure (men: 6.5% to 10.7%, women: 5.9% to 13.1%), 
moderate to severe liver disease (men: 0.1% to 0.7%, women: 
0.1% to 0.4%) and renal disease (men: 0.4% to 2.0%, women: 
0.3% to 1.1%) (Table 2, see Supplementary data).
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Table 1. Basic characteristics. Values are frequency (%) unless otherwise stated
  Alive after 30 days Dead within 30 days p-value Alive after 1 year Dead within 1 year p-value
Number 110,702 (90.1) 12,221 (9.9) – 88,541 (72.0) 34,382 (28.0) –
Male 32,968 (29.8) 5,175 (42.4)  
< 0.001 25,497 (28.8) 12,646 (36.8)  < 0.001Female 77,734 (70.2) 7,046 (57.6)  63,044 (71.2) 21,736 (63.2)
Median age (range) 80 (18–107) 86 (18–109) < 0.001 79 (18–107) 84 (18–111) < 0.001
Median Charlson-score (range) 1 (0–15) 1 (0–19) < 0.001 0 (0–16) 1 (0–19) < 0.001
Myocardial infarction 2,451 (2.2) 530 (4.3) < 0.001 1,722 (1.9) 1,259 (3.7) < 0.001
Congestive heart failure 10,229 (9.2) 1,490 (12.2) < 0.0001 7,772 (8.8) 3,947 (11.5) < 0.0001
Peripheral vascular disease 2,648 (2.4) 412 (3.4)  < 0.0001 1,978 (2.2) 1,082 (3.2) < 0.0001
Cerebrovascular disease 7,114 (6.4) 1,044 (8.5) < 0.0001 5,369 (6.1)  2,789 (8.1) < 0.0001
Dementia 4,381 (4.0)  849 (7.0)  < 0.0001 2,896 (3.3)  2,334 (6.8) < 0.0001
Chronic pulmonary disease 3,964 (3.6)  635 (5.2)  < 0.0001 2,973 (3.4)  1,626 (4.7) < 0.0001
Rheumatic disease 1,364 (1.2)  174 (1.4) 0.4 1,099 (1.2) 439 (1.3)  0.6
Peptic ulcer disease 3,778 (3.4) 568 (4.7) < 0.0001 2,832 (3.2) 1,514 (4.4) < 0.0001
Mild liver disease 705 (0.6) 82 (0.7)  0.7 575 (0.7) 212 (0.6) 0.5
Diabetes without chronic complication  1,065 (1.0) 148 (1.2) 0.008 815 (0.9)  398 (1.2)  0.0002
Diabetes with chronic complication 2,283 (2.1) 290 (2.4)  0.02 1,773 (2.0)  800 (2.3)  0.0004
Hemiplegia or paraplegia 300 (0.3) 17 (0.1) 0.006 250 (0.3)  67 (0.2)  0.007
Renal disease 746 (0.7) 204 (1.7) < 0.0001 483 (0.6)  467 (1.4)  < 0.0001
Any malignancy 2,862 (2.6) 475 (3.9) < 0.0001 2,074 (2.3)  1,263 (3.7)  < 0.0001
Moderate or severe liver disease 252 (0.2) 32 (0.3)  0.5 198 (0.2) 86 (0.3)  0.4 
Metastatic solid tumor 665 (0.6) 166 (1.4) < 0.0001 293 (0.3)  528 (1.5)  < 0.0001
AIDS/HIV 14 (0.0) 0 (0.0) 0.2 13 (0.0) 1 (0.0) 0.08
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Figure 1. Overall and sex-specifi c hip fracture incidence. O: fi tted values. X: observed values. P-values and 95% confi dence intervals are derived 
from negative binomial regression. Overall p < 0.0001, men p = 0.09, and women p < 0.0001,
Figure 2. Overall and sex-specifi c median age and interquartile range at time of fi rst hip fracture.
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Discussion
Hip fractures represent the most serious complication of osteo-
porosis in terms of morbidity, mortality, disability, and medi-
cal costs (Melton III 1993) and in 1993 it was estimated that 
the incidence of hip fractures would increase rapidly towards 
2016 (Kanis 1993). This hypothesis was further supported by 
another study in which it was projected that the increasing size 
of the elderly population would lead to a 50% increase in the 
number and cost of osteoporotic fractures by 2025 (Burge et 
al. 2007). While this tendency towards an increased incidence 
is supported by data from Austria (Mann et al. 2008), other 
studies from Denmark, Sweden, Canada, Switzerland, and 
Finland have shown a decline (Kannus et al. 2006, Abraha-
msen and Vestergaard 2010, Lippuner et al. 2011, Jean et al. 
2013, Korhonen et al. 2013, Nilson et al. 2013).
In line with these studies, we found that the incidence of hip 
fractures during the period 1999 to 2012 declined in the gen-
eral population by 25%. Earlier data have shown that hip frac-
tures occur more commonly in women than in men (Seeman 
1995). This difference is also supported by our results show-
ing a higher incidence of hip fractures for women during the 
whole period and even though the reduction in incidence was 
higher for women than for men the incidence was still twice as 
high in 2012 (181 vs. 93 per 100,000). Different explanations 
for the declining incidence have been proposed and include 
more widespread preventive measures, diagnosis, and treat-
ment of osteoporosis (Jean et al. 2013) which in part could 
explain why the incidence in the Austrian population was 
found to increase since the lack of a structured nationwide 
osteoporosis prevention approach has been reported (Mann 
et al. 2008). While anti-osteoporotic treatment has been pro-
posed as one of the major contributors to the declining inci-
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Figure 3. Overall and sex-specifi c 30-day mortality. O: fi tted values. X: observed values. P-values and 95% confi dence intervals are derived from 
negative binomial regression. Overall p = 0.9, men p = 0.5, and women p = 0.9.
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Figure 4. Overall and sex-specifi c 1-year mortality. O: fi tted values. X: observed values. P-values and 95% confi dence intervals are derived from 
negative binomial regression. Overall p = 0.4, men p = 0.5, and women p = 0.2.
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dence, it has also been suggested that the decrease is too large 
to be explained by the extent of anti-osteoporotic treatment 
with other potential explanations being changes in smok-
ing habits, obesity, improved general health, and vitamin D 
supplements (Abrahamsen and Vestergaard 2010). But even 
though a decreasing incidence has been found during the last 
decade in Denmark it has been proposed in a recent study by 
Rosengren et al. (2017), in which age-period-cohort effects 
for hip fractures were analyzed, that increasing fracture rates 
would be expected due to aging of more recent birth cohorts 
with a higher relative risk of sustaining a hip fracture. 
Hip fracture patients constitute one of the most vulnerable 
groups of patients with a high level of co-morbidity, with 
earlier data showing that 90% of male hip fracture patients 
suffered from some sort of chronic disease with two-thirds 
having a disease affecting sensory or motor function and one-
tenth having chronic alcoholism (Huuskonen et al. 1999). 
Likewise, different co-morbidities have been found to infl u-
ence the risk of sustaining a hip fracture. It has thus been 
shown that patients suffering from systemic lupus erythe-
matosus (Wang et al. 2013), Parkinson’s disease (Pouwels 
et al. 2013), dementia (Jorgensen et al. 2014), former stroke 
(Pouwels et al. 2009), heart failure, peripheral atheroscle-
rosis, ischemic heart disease (Sennerby et al. 2009), hemo-
dialysis, liver cirrhosis, prior fracture, and osteoporosis all 
have an increased risk of sustaining a hip fracture (Lin et al. 
2014). For COPD and asthma diverging results have been 
found with some reporting an increased risk of sustaining a 
fracture (Vestergaard et al. 2007) while others have not (Dam 
et al. 2010). The same applies to diabetes, where one study 
found an increased risk for patients suffering from type-2 dia-
betes (Schwartz et al. 2011) while another study found an 
increased risk only in patients with type-1 diabetes (Hoth-
ersall et al. 2014). Also, it has been found that patients who 
sustained a hip fracture were more likely to be women, living 
in long-term institutional care, using neuroleptics, dependent 
in activities of daily living (ADL), with a history of previous 
stroke with hemiparesis, Parkinsonism, and/or lower BMI 
than those who did not sustain a fracture after a fall on the hip 
(Willig et al. 2003). 
Since different co-morbidities have been found to increase 
the risk of sustaining a hip fracture, a general reduction in 
the disease burden in the population could be hypothesized 
as one of the reasons for the reduced incidence (Jorgensen 
et al. 2014) but, contrary to this, our results on the temporal 
development of the 17 included co-morbidities showed a trend 
with a decrease in prevalence of malignancy and dementia in 
women, while there was an increase in the prevalence of all 
remaining co-morbidities, except hemi- or paraplegia for both 
sexes, rheumatic diseases for women, and for men diabetes 
with complications, myocardial infarction, AIDS/HIV, and 
malignancy, with the largest increase in prevalence seen for 
congestive heart failure, moderate to severe liver disease, and 
renal disease. Of the included co-morbidities, the most preva-
lent in 1999 were congestive heart failure (men 6.5%, women 
5.9%), cerebrovascular disease (men 5.7%, women 4.8%), 
dementia (men 3.4%, women 3.2%), and chronic pulmonary 
disease (men 4.2%, women 2.5%) and during the period these 
co-morbidities were also subjected to the largest increments 
resulting in these also being the most prevalent in 2012 (con-
gestive heart failure: men 10.7%, women 13.1%, cerebrovas-
cular disease: men 7.4%, women 6.9%, dementia: men 4.0%, 
women 3.9%, and chronic pulmonary disease: men 5.1%, 
women 3.8%). 
While an increased disease burden would be expected to 
lead to an increase in incidence of fi rst hip fracture, this was 
not evident in our study. Reasons for the lack of increase in the 
incidence despite an increased disease burden could be better 
treatment of the individual diseases or more intensive diagnos-
tic measures resulting in earlier detection and treatment of the 
diseases and thus less impact on the individual patient. 
A potential reason for the higher disease rate we found 
could be increased age at the time of the fi rst hip fracture but 
the median age of patients sustaining a hip fracture remained 
almost unchanged at 81 for the whole population, 82 for 
women, and between 76 and 78 for men. Therefore, changes 
in age at the time of fracture do not seem to be a probable 
explanation for the changes in co-morbidity, which instead 
could be a consequence of more extensive diagnostic mea-
sures in the hospital setting in the years prior to the fracture.
During the study period, 30-day and 1-year mortality for 
the whole study population and for both sexes remained 
unchanged with no signifi cant changes. At the same time a 
higher mortality was evident for men at both 30 days and 1 
year. This difference in mortality has been shown earlier in 
several studies (Kellie and Brody 1990, Myers et al. 1991, 
Jacobsen et al. 1992). This is further supported by a meta-
analysis showing an excess mortality in both men and women 
after a hip fracture with higher mortality in men compared 
with women at all ages (Haentjens et al. 2010). The effect 
of co-morbidities on 30-day mortality has previously been 
investigated and an increased risk of early death was found 
in patients suffering from central nervous system diseases 
(dementia, Parkinson’s, hemiplegia), diabetes, circulatory 
disorders, nutritional defi ciencies, COPD, chronic renal dis-
ease, and other chronic diseases (liver, pancreas, intestine) 
(Barone et al. 2009). We also found a signifi cant association 
between low socioeconomic status and the risk of early death. 
As such, one would expect a concomitant increase in mortal-
ity rates with the increase in prevalence of the co-morbidities 
increases. One explanation for why this phenomenon was not 
observed in our study could be better and more effective treat-
ment of the different co-morbidities and/or better and faster 
management of hip fracture leading to a smaller effect on the 
mortality rates.
A limitation of this study is that it is only concerned with 
the fi rst hip fracture and as such data on incidence repre-
sent this and not the total incidence during the period, which 
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would be expected to be higher and, even though a washout 
period of 3 years was included, there is a small risk that 
the fracture included is not the fi rst but the second fracture 
or a complication from an earlier fracture. Also, while a 
decrease in incidence was found during the study period it 
is important to remember that the data shown are based on 
ICD-10 codes given on discharge and since no complete-
ness study has been performed it is possible that the inci-
dences shown could be infl uenced by lacking or inappro-
priate coding. Another limitation includes data on co-mor-
bidity, which are based on ICD-codes given to the patient 
on discharge. As such, a reason for the increase could be 
more focus on allocating codes to the patients on discharge 
at the end of the study period, but against this are results 
from a recent Danish study (Jørgensen et al. 2015) on 
patients undergoing fi rst-time coronary angiography during 
the period 2000 to 2009. In this study a general tendency 
towards lower prevalence of co-morbidities was found and 
when these results are compared with ours it seems likely 
that the increase in disease burden found in our study is real 
and not based on a change in coding practice. In addition, a 
correlation between time of inclusion and length of window 
of registration for co-morbidities is present in the study 
with patients included later having a longer window. While 
this would lead to a hypothetical increased risk of accu-
mulating co-morbidities for the patients included towards 
the end of the study period we are sure that any substantial 
co-morbidities would lead to contact with the healthcare 
system within a 3-year period and as such the risk would be 
minimally increased due to the effect of the initial 3-year 
data washout period in the study. Also, since our data do 
not contain information on changes in mortality and disease 
burden in the background population, it is not possible to 
conclude whether or not the changes are isolated to the hip 
fracture population or are a result of changes in the back-
ground population. The strengths of the study include the 
large number of patients in the study, covering all Danish 
hip fracture patients, and the use of the Danish national reg-
istries, which ensure that data are collected unbiasedly. As 
the study covers an entire population, it also increases the 
generalizability of the results and it is likely that the trends 
observed in the Danish population match those of other 
Western countries. 
In summary, this observational study shows that during 
the period 1999 to 2012 the incidence of fi rst hip fracture 
has declined for women but remained unchanged for men. 
For 30-day mortality, rates have increased for women even 
though there are no changes in 1-year mortality. On the con-
trary, 30-day mortality for men is unchanged while 1-year 
mortality has declined. When these results are compared with 
the relatively large increase in the prevalence of the different 
co-morbidities it does not seem likely that the increased dis-
ease burden is affecting the incidence or the mortality.
Supplementary data
Table 2 is available as supplementary data in the online
version of this article, http://dx.doi.org/10.1080/17453674. 
2018.1428436
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